These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29331515)

  • 1. MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.
    Rozanov DV; Rozanov ND; Chiotti KE; Reddy A; Wilmarth PA; David LL; Cha SW; Woo S; Pevzner P; Bafna V; Burrows GG; Rantala JK; Levin T; Anur P; Johnson-Camacho K; Tabatabaei S; Munson DJ; Bruno TC; Slansky JE; Kappler JW; Hirano N; Boegel S; Fox BA; Egelston C; Simons DL; Jimenez G; Lee PP; Gray JW; Spellman PT
    J Proteomics; 2018 Mar; 176():13-23. PubMed ID: 29331515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines.
    Antwi K; Hanavan PD; Myers CE; Ruiz YW; Thompson EJ; Lake DF
    Mol Immunol; 2009 Sep; 46(15):2931-7. PubMed ID: 19615748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
    Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
    Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
    Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
    Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.
    Morse MA; Secord AA; Blackwell K; Hobeika AC; Sinnathamby G; Osada T; Hafner J; Philip M; Clay TM; Lyerly HK; Philip R
    Clin Cancer Res; 2011 May; 17(10):3408-19. PubMed ID: 21300761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII.
    van Haren SD; Herczenik E; ten Brinke A; Mertens K; Voorberg J; Meijer AB
    Mol Cell Proteomics; 2011 Jun; 10(6):M110.002246. PubMed ID: 21467215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of a Predictive Cleavage Motif for Eluted Major Histocompatibility Complex Class II Ligands.
    Paul S; Karosiene E; Dhanda SK; Jurtz V; Edwards L; Nielsen M; Sette A; Peters B
    Front Immunol; 2018; 9():1795. PubMed ID: 30127785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
    Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
    Front Immunol; 2018; 9():776. PubMed ID: 29867922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
    Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
    Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS.
    Hofmann S; Glückmann M; Kausche S; Schmidt A; Corvey C; Lichtenfels R; Huber C; Albrecht C; Karas M; Herr W
    Mol Cell Proteomics; 2005 Dec; 4(12):1888-97. PubMed ID: 16112985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a definition of self: proteomic evaluation of the class I peptide repertoire.
    Hickman HD; Luis AD; Buchli R; Few SR; Sathiamurthy M; VanGundy RS; Giberson CF; Hildebrand WH
    J Immunol; 2004 Mar; 172(5):2944-52. PubMed ID: 14978097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
    Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
    Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
    Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
    Front Immunol; 2021; 12():662443. PubMed ID: 33936100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes.
    Bremers AJ; van der Burg SH; Kuppen PJ; Kast WM; van de Velde CJ; Melief CJ
    J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):77-85. PubMed ID: 8574469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes.
    Zhao W; Sher X
    PLoS Comput Biol; 2018 Nov; 14(11):e1006457. PubMed ID: 30408041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
    Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S
    J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of breast cancer peptide epitopes presented by HLA-A*0201.
    Hawkins OE; Vangundy RS; Eckerd AM; Bardet W; Buchli R; Weidanz JA; Hildebrand WH
    J Proteome Res; 2008 Apr; 7(4):1445-57. PubMed ID: 18345606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
    Peters HL; Tripathi SC; Kerros C; Katayama H; Garber HR; St John LS; Federico L; Meraz IM; Roth JA; Sepesi B; Majidi M; Ruisaard K; Clise-Dwyer K; Roszik J; Gibbons DL; Heymach JV; Swisher SG; Bernatchez C; Alatrash G; Hanash S; Molldrem JJ
    Cancer Immunol Res; 2017 Apr; 5(4):319-329. PubMed ID: 28254787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.